Eli Lilly unveils long-term data on Omvoh for Crohn’s disease

Eli Lilly (LLY) said that data from a phase 3 open-label extension study indicated that its IL-23 antagonist Omvoh (mirikizumab) led to steroid-free remission over three years.
Data from the VIVID-2 study found that at 152 weeks, corticosteroid-free clinical remission was 91.2%. Also, 82.1% of patients showed a ≥3-point reduction on the Urgency Numeric Rating Scale (UNRS).
In addition, 71.7% of patients saw a UNRS ≤2.